Last reviewed · How we verify

NCT03682913

Personalized Inhibitory Control Training for Compulsive Behavior Change

Status unknown NA Last updated 27 September 2018
What this trial tests

NA trial testing P-CIT protocol in OCD in 50 participants. Status unknown.

Timeline
1 July 2018
Primary endpoint
30 July 2019
30 August 2019

Quick facts

Lead sponsorHebrew University of Jerusalem
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment50
Start date1 July 2018
Primary completion30 July 2019
Estimated completion30 August 2019
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Hebrew University of Jerusalem

Who can join

18 and older, any sex, with OCD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obsessive-compulsive disorder (OCD) is a severe mental illness characterized by repetitive behaviors that a person feels compelled to perform. It has been demonstrated that stimuli in the environment can trigger the compulsive urge, perpetuating the OCD cycle. The main goal of the current proposal, which is based on exciting pilot data, is to test a novel computerized training program to create an association between OCD-related stimuli, which typically trigger the compulsive urge, and the brain system responsible for stopping. The idea is that once this system is triggered, it will be easier for patients to stop the compulsive urge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for OCD

Currently open trials in the same condition.

Other Hebrew University of Jerusalem trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03682913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing